Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin

International Journal of Pharmaceutics

Volumn 477, Issue 1-2, 2014, Pages 159-166

  Liu, Meina ^a   Cao, Wen ^a   Sun, Yinghua ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Hydroxypropyl cyclodextrin; Inclusion complex; NMR spectroscopy; Pharmacokinetics; Phase solubility studies; Repaglinide

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BENZENE; CARBENE; PIPERIDINE; REPAGLINIDE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTIDIABETIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; CARBAMIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; ELECTROSPRAY; ELIMINATION HALF-LIFE; FORELIMB; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; X RAY DIFFRACTION; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; DOG; LIQUID CHROMATOGRAPHY; MEDICINAL CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; SOLUBILITY; TANDEM MASS SPECTROMETRY;

ANIMALS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DOGS; FREEZE DRYING; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; PIPERIDINES; SOLUBILITY; TANDEM MASS SPECTROMETRY; X-RAY DIFFRACTION;

EID: 84908545544     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.10.038     Document Type: Article

References (34)

1. Ambavane, V., Patil, R., Ainapure, S., 2002. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. J. Postgrad. Med. 48, 246.
2. Aramə, C., Nicolescu, C., Nedelcu, A., Monciu, C.-M., 2011. Synthesis and characterization of the inclusion complex between repaglinide and sulfobutylether-β-cyclodextrin (Captisol®). J. Incl. Phenom. Macrocycl. Chem. 70, 421-428.
3. Bernini, A., Spiga, O., Ciutti, A., Scarselli, M., Bottoni, G., Mascagni, P., Niccolai, N., 2004. NMR studies of the inclusion complex between β-cyclodextrin and paroxetine. Eur. J. Pharm. Sci. 22, 445-450.
4. Blanco, J., Vila-jato, J.L., Otero, F., Anguiano, S., 1991. Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev. Ind. Pharm. 17, 943-957.
5. Brewster, M.E., Loftsson, T., 2007. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Del. Rev. 59, 645-666.
6. De Melo, N.F., Grillo, R., Rosa, A.H., Fraceto, L.F., 2008. Interaction between nitroheterocyclic compounds with β-cyclodextrins: phase solubility and HPLC studies. J. Pharm. Biomed. Anal. 47, 865-869.
7. Desai, N., Nagarsenker, M., 2013. Design and evaluation of self-nanoemulsifying pellets of repaglinide. AAPS PharmSciTech 14, 994-1003.
8. Desai, N.S., Bramhane, D.M., Nagarsenker, M.S., 2011. Repaglinide-cyclodextrin complexes: preparation: characterization and in vivo evaluation of antihyperglycemic activity. J. Incl. Phenom. Macrocycl. Chem. 70, 217-225.
9. Fronza, G., Mele, A., Redenti, E., Ventura, P.,1992. Proton nuclear magnetic resonance spectroscopy studies of the inclusion complex of piroxicam with β-cyclodextrin. J. Pharm. Sci. 81, 1162-1165.
10. Grell, W., Hurnaus, R., Griss, G., Sauter, R., Rupprecht, E., Mark, M., Luger, P., Nar, H., Wittneben, H., Müller, P., 1998. Repaglinide and related hypoglycemic benzoic acid derivatives. J. Med. Chem. 41, 5219-5246.
11. Hatorp, V., 2002. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 41, 471-483.
12. Kavitha, R., Sathali, A.A.H., 2012. Enhancement of solubility of repaglinide by solid dispersion technique. Int. J. Chem. Sci. 10, 377-390.
13. Liu, H., Yang, G., Tang, Y., Cao, D., Qi, T., Qi, Y., Fan, G., 2013. Physicochemical characterization and pharmacokinetics evaluation of β-caryophyllene/β-cyclodextrin inclusion complex. Int. J. Pharm. 450, 304-310.
14. Liu, J., Qiu, L., Gao, J., Jin, Y., 2006. Preparation: characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 312, 137-143.
15. Loftsson, T., Hreinsdóttir, D., Masson, M., 2005. Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 302, 18-28.
16. Ma, S.-X., Chen, W., Yang, X.-D., Zhang, N., Wang, S.-J., Liu, L., Yang, L.-J., 2012. Alpinetin/hydroxypropyl-β-cyclodextrin host-guest system: preparation, characterization, inclusion mode, solubilization and stability. J. Pharm. Biomed. Anal. 67, 193-200.
17. Mandić, Z., Gabelica, V., 2006. Ionization, lipophilicity and solubility properties of repaglinide. J. Pharm. Biomed. Anal. 41, 866-871.
18. Manvi, P., Narendra, P., Bhaskar, V., 2011. Preparation: characterization and in vitro evaluation of repaglinide binary solid dispersions with hydrophilic polymers. Int. J. Drug Dev. Res. 3, 111-121.
19. Marbury, T., Huang, W.-C., Strange, P., Lebovitz, H., 1999. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43, 155-166.
20. Marbury, T.C., Ruckle, J.L., Hatorp, V., Andersen, M.P., Nielsen, K.K., Huang, W.C., Strange, P., 2000. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther. 67, 7-15.
21. Marques, H., Hadgraft, J., Kellaway, I., 1990. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int. J. Pharm. 63, 259-266.
22. Muñoz, B.S., Martin, M., Del Castillo, B., Menendez, J., Vazquez, L., Lerner, D., 1996. Analytical applications of retinoid-cyclodextrin inclusion complexes: 1. Characterization of a retinal-beta-cyclodextrin complex. J. Pharm. Biomed. Anal. 14, 909-915.
23. Nicolescu, C., Aramə, C., Nedelcu, A., Monciu, C.-M., 2010. Phase solubility studies of the inclusion complexes of repaglinide with β-cyclodextrin and β-cyclodextrin derivatives. Farmacia 58, 620-628.
24. Purvis, T., Mattucci, M.E., Crisp, M.T., Johnston, K.P., Williams, R.O., 2007. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech 8, E52-E60.
25. Rizzo, M., Barbieri, M., Grella, R., Passariello, N., Barone, M., Paolisso, G., 2004. Repaglinide is more efficient than glimepiride on insulin secretion and postprandial glucose excursions in patients with type 2 diabetes A short term study. Diabetes Metab. 30, 81-89.
26. Schneider, H.-J., Hacket, F., Rüdiger, V., Ikeda, H., 1998. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 98, 1755-1786.
27. Scott, L.J., 2012. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs. 72, 249-272.
28. Seedher, N., Kanojia, M., 2008. Micellar solubilization of some poorly soluble antidiabetic drugs: a technical note. AAPS PharmSciTech 9, 431-436.
29. Sinswat, P., Matteucci, M.E., Johnston, K.P., Williams, R.O., 2007. Dissolution rates and supersaturation behavior of amorphous repaglinide particles produced by controlled precipitation. J. Biomed. Nanotechnol. 3, 18-27.
30. 1H NMR studies on host-guest interaction of paeonol and two of its isomers with β-cyclodextrin. Int. J. Pharm. 316, 7-13.
31. Yang, L.-J., Ma, S.-X., Zhou, S.-Y., Chen, W., Yuan, M.-W., Yin, Y.-Q., Yang, X.-D., 2013. Preparation and characterization of inclusion complexes of naringenin with β-cyclodextrin or its derivative. Carbohydr. Polym. 98, 861-869.
32. Yin, L.-F., Huang, S.-J., Zhu, C.-L., Zhang, S.-H., Zhang, Q., Chen, X.-J., Liu, Q.-W., 2012. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev. Ind. Pharm. 38, 1371-1380.
33. Zawar, L.R., Bari, S.B., 2011. Preparation: characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion. Chem. Pharm. Bull. (Tokyo) 60, 482-487.
34. Zoeller, T., Dressman, J.B., Klein, S., 2012. Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions. Int. J. Pharm. 430, 176-183.